Results 81 to 90 of about 1,879,819 (343)

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

open access: yesMolecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece   +18 more
wiley   +1 more source

Recurrence of Autoimmune Hepatitis After COVID-19 Vaccination [PDF]

open access: diamond, 2022
Jon Elliott D Brubaker   +2 more
openalex   +1 more source

Fractional recurrence in discrete-time quantum walk

open access: yes, 2010
Quantum recurrence theorem holds for quantum systems with discrete energy eigenvalues and fails to hold in general for systems with continuous energy.
A. Ambainis   +37 more
core   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

open access: yesMolecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He   +8 more
wiley   +1 more source

The Cube Recurrence

open access: yes, 2004
We construct a combinatorial model that is described by the cube recurrence, a nonlinear recurrence relation introduced by Propp, which generates families of Laurent polynomials indexed by points in $\mathbb{Z}^3$.
Carroll, Gabriel D., Speyer, David E
core   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

Diagnostic Value of PET/CT for Ovarian Cancer Recurrence or Metastasis in Postoperative Patients With Elevated Serum CA125 Levels: A Systematic Review and Meta‐Analysis

open access: yesCancer Innovation
Background Ovarian cancer patients with elevated serum CA125 levels after operation have a high incidence of relapse or metastasis. 18F‐FDG PET/CT is an effective imaging method for identifying recurrent or metastatic lesions.
Zuowei Zou   +6 more
doaj   +1 more source

Stroke recurrence in the different subtypes of ischemic stroke. The importance of the intracranial disease

open access: yesArquivos de Neuro-Psiquiatria
The aim of the study was to analyze the long-term recurrence rate in patients with a first-ever ischemic stroke secondary to intracranial large artery atherosclerosis (LAA) in a Brazilian population.
Marcos C Lange   +7 more
doaj   +1 more source

Predicting Recurrence after a First Unprovoked Venous Thromboembolism: Retrospective Validation of the DAMOVES Score

open access: yesProceedings, 2018
Unprovoked venous thromboembolism is associated with a 5 to 27% annual risk of recurrence after discontinuation of anticoagulation, and indefinite anticoagulation is recommended if the bleeding risk is low to moderate.
A. I. Franco Moreno   +10 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy